Lecanemab: Promising Cure or Expensive Gamble?
The debate over lecanemab, one of the first Alzheimer’s drugs to slow cognitive decline, is heating up.
The debate over lecanemab, one of the first Alzheimer’s drugs to slow cognitive decline, is heating up.
The FDA advisory panel has recommended the approval of donanemab, a new Alzheimer’s drug by Eli Lilly, after voting unanimously that it effectively slows early-stage Alzheimer’s disease and that its benefits outweigh the risks.